Efficacy of the consolidation chemotherapy after autologous stem cell transplantation in refractory/relapse lymphoma

俞杨; 樊星; 王苓; 唐暐; 胡炯

doi:10.3969/j.issn.1007-3969.2014.10.008

您当前的位置：

首页 >

文章列表页 >

Efficacy of the consolidation chemotherapy after autologous stem cell transplantation in refractory/relapse lymphoma

更新时间：2025-12-31

- Efficacy of the consolidation chemotherapy after autologous stem cell transplantation in refractory/relapse lymphoma
- China Oncology Vol. 24, Issue 10, Pages: 761-764(2014)
- 作者机构：
  
  上海交通大学医学院附属瑞金医院血液科,上海,200025
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.10.008
  CLC：
- Published Online：12 November 2014，
  
  Published：12 November 2014
- 稿件说明：
移动端阅览
俞杨,樊星,王苓,唐暐,胡炯. 复发/难治性淋巴瘤患者自体干细胞移植后巩固化疗的疗效分析[J]. 中国癌症杂志, 2014, 24(10): 761-764.

俞杨, 樊星, 王苓, et al. Efficacy of the consolidation chemotherapy after autologous stem cell transplantation in refractory/relapse lymphoma[J]. China Oncology, 2014, 24(10): 761-764.
俞杨,樊星,王苓,唐暐,胡炯. 复发/难治性淋巴瘤患者自体干细胞移植后巩固化疗的疗效分析[J]. 中国癌症杂志, 2014, 24(10): 761-764. DOI： 10.3969/j.issn.1007-3969.2014.10.008.

俞杨, 樊星, 王苓, et al. Efficacy of the consolidation chemotherapy after autologous stem cell transplantation in refractory/relapse lymphoma[J]. China Oncology, 2014, 24(10): 761-764. DOI： 10.3969/j.issn.1007-3969.2014.10.008.

摘要

背景与目的：目前，大剂量化疗+自体造血干细胞移植(autologousetemcell transplantation，auto-HSCT)是部分复发/难治淋巴瘤的首选治疗方案，但其再次复发率仍较高。因此我院血液科骨髓移植病区尝试对自体干细胞移植治疗后高危复发的难治性患者进行巩固化疗，并对其临床疗效进行比较分析。方法：回顾性分析38例接受auto-HSCT治疗的复发/难治性淋巴瘤患者的临床资料。将auto-HSCT治疗后给予巩固化疗的19例患者作为治疗组，与仅接受auto-HSCT治疗的19例进行对照(对照组)。巩固化疗方案为Mini-BEAM或减低剂量CBV，每次化疗间隔2～3个月，共2个疗程。以auto-HSCT为随访起点，比较2组患者无进展生存期(progression-free survival，PFS)和总体生存期(overall survival，OS)的差异。结果：治疗组及对照组中位随访时间分别为17.2和7.5个月。意向性分析显示2组中位PFS分别为24.7和7.8个月，治疗组明显优于对照组(P=0.029)。OS呈现一定差异的趋势(P=0.055)。完成治疗分析显示2组中位PFS分别为24.7和5.2个月，治疗组亦优于对照组(P=0.01)。结论：针对高危恶性淋巴瘤患者，在自体移植基础上进一步予以巩固化疗，可延迟疾病复发、降低复发率，延长患者生存时间。

Abstract

Background and purpose: High-dose chemotherapy followed by autologous stem cell transplantation (auto-HSCT) is considered as the first line treatment for patients with relapse/refractory lymphoma after conventional chemotherapy. However

most of these patients still relapse the second time. The purpose of this study was to analyze the efficacy of the consolidation chemotherapy after autologous stem cell transplantation (HSCT) refractory/relapse lymphoma in high risk. Methods: A total of 38 patients with relapsed/refractory lymphoma including Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) were included

who were underwent auto-HSCT in our transplantation department from Jan. 2010 to Dec. 2013. In treatment group

19 patients received 2 courses of consolidation chemotherapy after auto-HSCT every 2 to 3 months

with the regimen of mini-BEAM or modified mini-CBV. Another 19 patients had no chemotherapy after auto-HSCT as control group. Results: The median follow-up duration was 17.2 and 7.5 months in the treatment and control group respectively. The follow-up data demonstrated prolonged progression-free survival (PFS) in the treatment group than the control group [24.7 months vs 7.8 months

P=0.029 under intend-to-treat analysis ITT; 24.7 months vs 5.2 months

P=0.01 under per protocol analysis(pp)]. There is also a trend of improved overall survival (OS) in the treatment group (P=0.055

ITT). Conclusion: Consolidation chemotherapy after auto-HSCT for refractory/relapsed lymphoma patients delay the relapse and tend to improve the overall relapse rate

关键词

Keywords

references

Views

3647

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas

Detection of CD30 expression in lymphomas: status and challenges

Clinical practice optimization exploration and future prospects of autologous hematopoietic stem cell transplantation for lymphoma

Updates on the WHO classification of the mucosal lymphomas of the head and neck

The toxicity of chimeric antigen receptor T-cell immunotherapy in B-cell lymphoma: a Meta-analysis

Related Author

Pathology Expert Group CD30-Positive Lymphoma

CD30阳性淋巴瘤病理专家组

Xiaoqiu LI

Zhengming JIN

李小秋

勋

张锡友

峰

Related Institution

Department of Pathology, Fudan University Shanghai Cancer Center; Department ofOncology, Shanghai Medical College, Fudan University

苏州大学附属第一医院,江苏省血液病研究所,国家血液系统疾病临床医学研究中心

复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系

首都医科大学附属北京天坛医院神经肿瘤综合治疗病区

首都医科大学附属北京世纪坛医院脑胶质瘤科

AI问答

⁰